In Brief: Exogen
This article was originally published in The Gray Sheet
Executive Summary
Exogen: Health Care Financing Administration denies Medicare reimbursement coverage for the firm's Sonic Accelerated Fracture Healing System, Exogen announces Aug. 23. The Piscataway, New Jersey firm says it is "disappointed" in HCFA's determination and plans "to aggressively pursue all avenues to reverse this decision." Exogen says it presented HCFA with "clinical and economic outcome data" on 105 Medicare patients treated with the system and reported a 94% healing rate, adding that it "estimates that a significant economic benefit well above the cost of the SAFHS therapy has been realized by these patients." The firm also reports that it has not recorded any revenues from Medicare sales...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.